Editorial Commentary
The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly
Abstract
Immune checkpoint inhibitors (ICI) have had significant impact on the treatment of metastatic lung cancer patients with initial pivotal studies showing survival benefit in second line setting favoring ICI use compared to chemotherapy (1-4). Subsequently, ICI has shown a benefit in first line setting with single agent pembrolizumab (5) or in combination with chemotherapy based on PD-L1 expression results (6-9).
